Across the continent, governments and hospitals are purchasing robotics systems from abroad as well as developing the technologies themselves.
This mode of personalized medicine helps doctors make more informed decisions related to drug therapies.
The race to apply AI to medical treatment is rapidly accelerating in China and Japan.
MRI-compatible pacemakers are among the technologies gaining traction.
Although an expensive and challenging regulatory market, Japan’s aging population offers plenty of opportunities for device companies.
It’s critical to understand the characteristics of this country’s market to determine the most effective steps.
With the exception of a few countries, Asia’s disease management industry is relatively unstructured.
While Western countries still have more medical device startups than the rest of the world, more new medtech startups are popping up in Asia than ever before.
As standalone software becomes increasingly sophisticated, a number of regulatory bodies have begun to draft separate guidelines to ensure quality control, expedite product approval, and improve patient access to new technologies.
Global sports medicine is predicted to grow to around $35 billion by 2022, with the Asian market growing at a compound annual growth rate of nearly 7 percent.